Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
December 05, 2023 08:47 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
December 01, 2023 08:14 ET
|
Clearmind Medicine Inc.
The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program Tel Aviv, Israel / Vancouver, Canada, Dec. 01, 2023 (GLOBE...
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
November 28, 2023 08:25 ET
|
Clearmind Medicine Inc.
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite Tel Aviv, Israel / Vancouver, Canada, Nov. ...
Clearmind Medicine to Participate in Traditional vs. Novel Psychedelics Virtual Event with Leading Industry Figures
November 27, 2023 08:55 ET
|
Clearmind Medicine Inc.
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space Tel Aviv,...
Clearmind Medicine Announces 1-for-30 Reverse Share Split
November 21, 2023 08:15 ET
|
Clearmind Medicine Inc.
Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Clearmind...
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice and Plan for Immediate Recompliance
November 17, 2023 16:15 ET
|
Clearmind Medicine Inc.
As part of the Company’s plan for recompliance, the Company’s shareholders approved a reverse stock split on November 14, 2023. Tel Aviv, Israel / Vancouver, Canada, Nov. 17, 2023 (GLOBE...
Clearmind Medicine Announces Shareholders Meeting Results
November 15, 2023 07:37 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on...
Clearmind Medicine to Pioneer Psychedelic Clinical Trials for Alcohol Use Disorder with Ivy League Universities
November 09, 2023 09:20 ET
|
Clearmind Medicine Inc.
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada,...
Clearmind Medicine to Present at the 8th Annual Dawson James Conference on October 12th
October 05, 2023 09:00 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...
Clearmind Medicine Closes US$2.25 Million Public Offering
September 18, 2023 12:16 ET
|
Clearmind Medicine Inc.
Tel Aviv, Israel / Vancouver, Canada, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind”), a biotech company focused on the discovery and...